
## Aden Ka-Yin Chan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2001173/publications.pdf Version: 2024-02-01



ΔΠΕΝ ΚΛ-ΥΙΝ ΟΗΛΝ

#	Article	IF	CITATIONS
1	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
2	Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro-Oncology, 2017, 19, 1327-1337.	1.2	177
3	TERT promoter mutations contribute to subset prognostication of lower-grade gliomas. Modern Pathology, 2015, 28, 177-186.	5.5	107
4	IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. Brain Pathology, 2020, 30, 541-553.	4.1	73
5	Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors. Modern Pathology, 2014, 27, 332-342.	5.5	45
6	Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget, 2016, 7, 5030-5041.	1.8	45
7	TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data. Critical Reviews in Oncology/Hematology, 2017, 120, 1-9.	4.4	44
8	Combination genetic signature stratifies lower-grade gliomas better than histological grade. Oncotarget, 2015, 6, 20885-20901.	1.8	42
9	FGF18, a prominent player in FGF signaling, promotes gastric tumorigenesis through autocrine manner and is negatively regulated by miR-590-5p. Oncogene, 2019, 38, 33-46.	5.9	41
10	<scp>MIR</scp> â€137 Suppresses Growth and Invasion, is Downregulated in Oligodendroglial Tumors and Targets <scp>CSE1L</scp> . Brain Pathology, 2013, 23, 426-439.	4.1	39
11	SRGAP1, a crucial target of miR-340 and miR-124, functions as a potential oncogene in gastric tumorigenesis. Oncogene, 2018, 37, 1159-1174.	5.9	36
12	Pediatric low-grade gliomas can be molecularly stratified for risk. Acta Neuropathologica, 2018, 136, 641-655.	7.7	36
13	TERTpromoter mutations contribute toIDHmutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas. Oncotarget, 2015, 6, 24871-24883.	1.8	34
14	Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9. Laboratory Investigation, 2018, 98, 968-976.	3.7	33
15	Clinical and mutational profiles of adult medulloblastoma groups. Acta Neuropathologica Communications, 2020, 8, 191.	5.2	30
16	Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival. PLoS ONE, 2013, 8, e67421.	2.5	25
17	The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis. Laboratory Investigation, 2017, 97, 946-961.	3.7	24
18	Surgically treated incidentally discovered low-grade gliomas are mostly IDH mutated and 1p19q co-deleted with favorable prognosis. International Journal of Clinical and Experimental Pathology, 2014, 7, 8627-36.	0.5	24

Aden Ka-Yin Chan

#	ARTICLE	IF	CITATIONS
19	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget, 2016, 7, 64615-64630.	1.8	22
20	Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. Neuro-Oncology Advances, 2019, 1, vdz015.	0.7	22
21	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Modern Pathology, 2021, 34, 1245-1260.	5.5	21
22	<i>TP53</i> and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas. New England Journal of Medicine, 2016, 375, 2206-2208.	27.0	16
23	STK3 promotes gastric carcinogenesis by activating Ras-MAPK mediated cell cycle progression and serves as an independent prognostic biomarker. Molecular Cancer, 2021, 20, 147.	19.2	13
24	Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. Neuro-Oncology, 2017, 19, 1008-1010.	1.2	12
25	TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. International Journal of Clinical and Experimental Pathology, 2015, 8, 11485-94.	0.5	11
26	Establishment and characterization of meningioma patient-derived organoid. Journal of Clinical Neuroscience, 2021, 94, 192-199.	1.5	9
27	Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication. Frontiers in Oncology, 2022, 12, 839302.	2.8	3
28	Oligodendrogliomas in pediatric and teenage patients only rarely exhibit molecular markers and patients have excellent survivals. Journal of Neuro-Oncology, 2018, 139, 307-322.	2.9	2
29	Lowâ€grade BRAF V600E mutant oligodendrogliomaâ€like tumors of children may show EGFR and MET amplification. Brain Pathology, 2021, 31, 211-214.	4.1	2
30	HG-07ABERRANTLY EXPRESSED microRNAs IN BRAF MUTATED YOUNG ADULT GBM. Neuro-Oncology, 2016, 18, iii49.2-iii49.	1.2	1
31	Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas. Clinical Neurology and Neurosurgery, 2021, 208, 106882.	1.4	1